Material and Methods: Analysis of T-lymphocyte subsets was performed in 39 patients with stage III gastric adenocarcinoma who had undergone a curative gastric resection and postoperative chemotherapy. Circulating T-lymphocyte subsets were measured on venous blood by using flow cytometry and monoclonal antibodies on preoperative day 1, and postoperative months 1, 3, and 6.
INTRODUCTION
The immune system plays a critical role in limiting aberrant cell growth leading to cancer. In patients with advanced stages of cancer, the normal immune response is frequently observed to be altered or impaired (1-3). Typically, immune function is evaluated by using parameters reflecting either functional or numerical changes of lymphocytes. These changes in peripheral blood lymphocytes have been reported in patients with widely ranging primary types of cancer (4-6). Studies have demonstrated both a reduction in the number of peripheral blood T-lymphocytes and the proportion of helper/inducer (CD4 + ) to suppressor/cytotoxic (CD8 + ) T-lymphocytes, which are thought to play a key role in cellmediated immunity (5-7).
Gastric cancer is the leading cause of cancer deaths in Korea. Despite multi-faceted treatment regimens, control of this cancer at an advanced stage remains difficult. Reductions in the numbers of CD4 + and CD8 + T-cells have been observed in patients with advanced stages of gastric cancer (8). However, it is not clear whether such changes in T-lymphocyte subsets are preoperative or postoperative events in patients receiving surgical intervention. The aim of this study was to evaluate the changes of T-lymphocyte subsets during postoperative adjuvant chemotherapy and the relationship between T-lymphocyte subsets and tumor recurrence in AJCC (American Joint Committee on Cancer) stage III gastric cancers (9). The authors prospectively investigated T-lymphocyte subsets in patients with AJCC stage III gastric cancer who had undergone a gastric resection with D2 lymph node dissection with curative intent and postoperative chemotherapy.
MATERIAL AND METHODS

PATIENTS CHARACTERISTICS
Forty-seven patients who had undergone a curative gastric resection with D2 lymph node dissection by the same surgeon for histologically proven AJCC stage III gastric adenocarcinoma were considered eligible for this study. Patients were identified preoperatively between March 1, 1995 and February 28, 1996. Data regarding patients' clinical characteristics and lymphocyte subsets were collected and evaluated by a different surgeon from the operator. Patients were excluded from participation in this study if: a) preoperative or postoperative transfusion was required during follow-up; b) death occurred unrelated to primary cancer; c) patients were not able to maintain the planned schedule for blood sampling or administration of the postoperative six month chemotherapy cycle. Reasons for failure to maintain compliance with blood draws and chemotherapy included: postoperative major complications such as single or multiple organ failure, sepsis, pneumonia, anastomosis leakage, intra-abdominal infection, or abscess formation, reoperation was necessary, patients failed to maintain regular follow-up, or recurrence was identified within the first six months after operation. After exclusion criteria, 39 patients were eligible and enrolled in this study. These patients were followed up regularly at our clinic between March 1, 1995 and February 28, 2000. On the basis of clinical examinations, ultrasound, abdominal computed tomography, and tumor markers, patients were defined as having tumor recurrence (n = 17) or not (n = 22). All patients were treated with chemotherapy monthly during the first six-months after the operation. 5-FU was administered by continuous infusion at a dosage of 500 mg/m 2 /day, on days 1 through 5. Bolus cisplatin was given at a dosage of 60 mg/m 2 /day on day 1. The first chemotherapy cycle was started between postoperative days 7 and 10. The second through sixth chemotherapy cycles were performed every 4weeks after the first chemotherapy treatment. All patients were hospitalized during the chemotherapy. The peripheral blood sample from preoperative day 1 was taken on the day before operation for evaluating T-lymphocyte subsets. The blood sample from postoperative months 1 and 3 were taken on the day prior to the initiation of the 2 nd and 4 th chemotherapy cycles, respectively. The blood sample of postoperative 6 month was taken 3 weeks after the 6 th chemotherapy cycle. This study was performed after informed consent was obtained.
METHODS FOR EVALUATING LYMPHOCYTE SUBSETS
Ten milliliters of heparinized blood were taken from each patient. Aliquots (100 µ l) of whole blood were incubated in the dark, with 20 µ l of the following monoclonal antibodies: CD3 + fluorescein isothiocyanate (FITC)/CD19 + Rphycoerythrin (RPE) for mature T-cell/B-cell, CD4 + FITC/ CD8 + RPE for helper/suppressor T-cell, CD3 + FITC/CD16 + plus 56 + RPE for T-cell/natural killer (NK) cell, CD4 + FITC/ CD25 + RPE for activated T-cell, and immunoglobulin-G FITC plus RPE for control (Beckton Dickinson, San Jose, CA). A total of 2 ml of fluorescence-activated cell sorterlysing solution (Beckton Dickinson, San Jose, CA) was then added, mixed, and resuspended in phosphate-buffered saline. T-lymphocyte subset distribution was evaluated using the FACScan flow cytometer (Beckton Dickinson, Mountain View, CA). Results were expressed as the total number and percentage of positive cells counted.
STATISTICAL AND SURVIVAL ANALYSIS
The data were analyzed using the SPSS statistical program (SPSS Inc., Chicago, IL, U.S.A.). Mean values were compared using the Mann-Whitney U test and continuous data at multiple time points in the same individual were analyzed by the repeated measures ANOVA. The categorical data between the two groups were analyzed using the chisquare and Fisher's exact test. Actual survival was calculated with the Kaplan-Meier method (10) . Significance between survival curves of populations was evaluated using the log-rank test. Statistical significance was assumed at p < 0.05. Death that was confirmed to be caused by the gastric cancer was treated as an endpoint for survival.
RESULTS
CLINICAL CHARACTERISTICS
Eight patients were excluded from this study because they had recurrence within the first six months after operation (n = 3), postoperative major complications (n = 1), postoperative transfusion (n = 1), reoperation for mechanical obstruction due to postoperative adhesion (n = 1), and failed to be followed up regularly (n = 2). These patients were unable to maintain the planned schedule for taking the blood sampling or administration of the postoperative chemotherapy cycle for six months. Among all patients, the most common type of postoperative recurrence (n = 17) was hematogenous dissemination to liver, lung, and bone sites (n = 8). Recurrence also occurred from peritoneal implants (n = 4), distant lymph node metastasis including paraaortic and extra-peritoneal lymph nodes (n = 3), and locoregional recurrence (n = 2). The clinical and histopathological details of all investigated patients with AJCC stage III gastric cancer are shown in Table 1 . There was no statistically significant difference between the recurrence and non-recurrence groups based on age, sex ratio, AJCC stage, depth of tumor invasion, regional lymph node metastasis, tumor differentiation, Borrmann classification, and operation method. Median disease-free survival and overall survival time were 26.2 and 35.2 months in the recurrence group, respectively. The 5-year disease-free survival rate of the patients with stage 3a (n = 27) and 3b (n = 12) was 57.1 % and 33.3 %, respectively (p = 0.06; Fig. 1A) . The overall 5-year survival rate of patients with stage 3a and 3b disease was 70.3 % and 48.6 %, respectively (p = 0.13; Fig 1B) .
TOTAL LEUKOCYTE COUNTS AND CD3 + T-CELLS
The mean values of total leukocyte counts were not beyond the normal range in this study, however, they progressively decreased in both the recurrence and non-recurrence groups during postoperative chemotherapy. There was no statistical difference between the two groups ( Fig. 2A) . CD3 + T-cells were consistently higher in the non-recurrence group (mean 1231.4 cell/mm 3 , 95 % CI = 1054.9 to 1407.9 cell/ mm 3 ) than in the recurrence group (1073.5 cell/mm 3 , 820.9 to 1326.1 cell/mm 3 ) during the observation period. CD3 + T-cell levels sharply declined on postoperative month 1 (p < 0.05) compared with counts on preoperative day 1 (the recurrence group; 1317.6 (Fig. 2B ). However, total leukocyte counts showed no significant difference between stage 3a and 3b groups, except on preoperative day 1 (9.742 10 3 /mm 3 , 7.883 to 11.473 10 3 /mm 3 vs. 6.700 10 3 /mm 3 , 5.299 to 8.101 10 3 /mm 3 ; p < 0.05 (Fig. 3A) . CD8 + T-cell counts slightly increased in the recurrence group, compared with preoperative values. However, there was no significant difference between the two groups during the observation period (Fig. 3B) . Except for postoperative month 3, the CD4 + /CD8 + ratios showed higher values in the nonrecurrence group than in the recurrence group (Fig. 3C) . CD4 + and CD8 + T-cells, and the CD4 + /CD8 + ratio between stage 3a and 3b were not statistically significant different during the observation period. CD16 + , CD19 + , AND CD25 + T-CELLS CD16 + , CD19 + , and CD25 + T-cell counts between the recurrence and non-recurrence groups are shown in Figures 4A, 4B , and 4C, respectively. CD16 + T-cells increased in both groups after operation, as compared with the preoperative values. CD19 + T-cells remained relatively stable in both groups during the observation period. CD25 + T-cells decreased in both groups at postoperative month 1, compared with preoperative values, and increased at postoperative months 3 and 6. However, the mean values of CD16 + , CD19 + , and CD25 + T-cells were not statistically different between the two groups at any time point during the observation period. Except for the preoperative values of CD16 + T-cells (397.1 cell/mm 3 , 297.5 to 496.6 cell/mm 3 vs. 240.0 cell/mm 3 , 186.9 to 293.0 cell/mm 3 ), CD16 + , CD19 + , and CD25 + T-cells between stages 3a and 3b showed no statistically significant difference during the observation period.
DISCUSSION
Although we do not completely understand the mechanism that underlies the specific immunologic alterations, both functional and quantitative defects in immunity have been reported in advanced cancers (11, 12) . There has been considerable interest in the hypothesis that impaired immunity is common in cancer patients, and unless reversed together with anti-cancer treatment, tumor recurrence may occur (13) (14) (15) . Indeed, a number of studies examining the immune status and prognosis of patients with solid neoplasms have reported that there is a reduction in both the number of peripheral blood T-lymphocytes and the proportion of CD4 + to CD8 + T-cells, which are thought to play an important role in cell-mediated immunity (5-7). The measurement of T-lymphocyte subsets has been reported as a useful clinical indicator of immunosuppression in a number of disease states. Nevertheless, it remains difficult to establish the actual influence of these changes on the degree of immunosuppression. Immunosuppression is likely a multi-factorial deficit affecting multiple aspects of the immune system, and for this reason, a single measurement is unlikely to be a specific indicator of total immunologic status (16) . In this study, the patients' preoperative values of CD3 + , CD4 + , CD8 + , CD16 + and CD19 + T-cells and CD4 + /CD8 + ratio were similar to the results of previous studies of gastric cancer patients in Korea. Similarly, these studies showed that all values of T-lymphocyte subsets were lower in gastric cancer patients than those of healthy controls (4). Although the total number of white blood cells showed a significant increase in gastric cancer patients compared with healthy controls, the percentage of lymphocytes was the same (17) . However, other authors reported that the absolute number and percentage of CD3 + and CD4 + T-cells in peripheral blood from the advanced gastric cancer patients were significantly lower than those from normal healthy controls (18, 19) . The number of CD3 + and CD4 + T-cells and the percentage of CD4 + T-cells decreased significantly with more advanced stages of cancer. Quantitative and qualitative changes in T-lymphocyte subsets in advanced stages of cancer may be the factors responsible for immunosuppression (20) . The numbers of CD4 + , CD8 + , CD16 + , and CD19 + T-cells were significantly decreased and the CD4 + /CD8 + ratio increased in patients with gastric cancer before operation compared with those in healthy controls (4). However, others have reported that a decrease in the CD4 + /CD8 + ratio was found with a progression of gastric cancer (20) . The finding that T-lymphocyte subsets were de- pressed differentially with the stage suggested that the host immunity was impaired with the progression of gastric cancer (6).
In this study, immunosuppression associated with CD3 + and CD4 + T-cell depression was not identified when comparing stage 3a and 3b groups. Furthermore, CD3 + T-cells showed higher values in stage 3b rather than in stage 3a during the postoperative chemotherapy. However, the numbers of CD3 + and CD4 + T-cells were consistently higher in the non-recurrence group throughout the observation period. Therefore, these results indicate that the depressed CD3 + and CD4 + T-cells have a potential to affect tumor recurrence in patients with AJCC stage III gastric cancer who had undergone a gastric resection with D2 lymph node dissection with curative intent and postoperative adjuvant chemotherapy.
In conclusion, although the number of patients enrolled in this study was relatively small to fully evaluate postoperative host immunity and recurrence, the results of this study suggest that the immunosuppression associated with CD3 + and CD4 + T-cell depression is a risk factor for postoperative recurrence in patients with stage III gastric cancer.
